Company / SG&A Expense
AXIM BIOTECHNOLOGIES, INC. SG&A Expense History
FY2015-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$2.2M
FY2023
5-year range
$1.8M / $4.1M
FY2019-FY2023
Trend
-45.2%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $3M to $2M over the past 5 years.
Based on SEC 10-K filings.
$2M in FY2023 with a 5-year CAGR of -6.7%.
Improved from $3M to $2M over the past 5 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -6.7%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -6.7%, indicating a declining trend.
- In FY2023, sg&a expense decreased 45.2% year-over-year.
- Peak sg&a expense was recorded in FY2015.
- Lowest sg&a expense in the period was in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -18.18 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2023 | $2.2M | -45.2% |
| FY2022 | $4.1M | +29.0% |
| FY2018 | $3.2M | +76.0% |
| FY2017 | $1.8M | -47.3% |
| FY2016 | $3.4M | -64.0% |
| FY2015 | $9.5M | - |
| FY2013 | - | - |
| FY2012 | - | - |
| FY2011 | - | - |
As of FY2023 · SEC 10-K · Updated Jun 29, 2026